Diagnosis and Prognosis Utility of microRNA-205 Expression in Prostate Carcinogenesis: Meta-Analysis and Bioinformatics Study
DOI:
https://doi.org/10.55677/IJCSMR/V4I3-01/2024Keywords:
miR-205, prostate, differential expression, meta-analysis, bioinformaticsAbstract
Background: Prostate cancer (PCa) is a common disease that affects millions of men worldwide. Precise and non-invasive markers for diagnosing and prognosing PCa are vital to enhance patient management. MicroRNAs have been proposed as non-invasive biomarkers. We performed a meta-analysis and a bioinformatics study of miR-205 to give a full assessment of its diagnostic and prognostic relevance.
Materials and methods: We searched all published papers on miR-205 expression in PCa up to April 30, 2023 using PubMed, sciencedirect, Google Scolar, Web of Science. We used RevMan software to Meta-analyze the included literature. A bioinformatics investigation of genes and pathways that may be targets of the mature miR-205-5p impact was also performed.
Results: The pooled standardized mean difference of miR-205 differential expression in PCa compared to normal tissue, in primary and progressed cancer and hazard ratio were -1.58; p˂0.001, -0.23; p=0.06 and 2.61; p=0.002 respectively. Bioinformatics analysis revealed that miR-205-5p may regulate YAP1 and the Hippo signaling pathway.
Conclusion: The current study found that miRNA-205 is downregulated in PCa and have a significant prognostic value. MiRNA-205 may have a role in prostate carcinogenesis via regulating YAP1 through the Hippo signaling pathway.
References
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Aug 15;149(4):778–89.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7–33.
Gasinska A, Jaszczynski J, Rychlik U, Łuczynska E, Pogodzinski M, Palaczynski M. Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy. Pathol Oncol Res POR. 2020 Apr;26(2):1049–56.
Gazzaz H, Tetou M, Oukabli M, Bouzidi AA, Alami M, Dami A, et al. Symptoms presentation and aggressiveness pattern of prostate cancer in a Moroccan population. Rev DÉpidémiologie Santé Publique. 2021;69:S45.
Kim T, Reitmair A. Non-Coding RNAs: Functional Aspects and Diagnostic Utility in Oncology. Int J Mol Sci. 2013 Mar 1;14(3):4934–68.
Du T, Zamore PD. microPrimer: the biogenesis and function of microRNA. Dev Camb Engl. 2005 Nov;132(21):4645–52.
Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature. 2005 Jun 9;435(7043):745–6.
Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. 2010 Jul 15;127(2):394–403.
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and mRNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008 Aug 1;68(15):6162–70.
Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010 Mar 1;126(5):1166–76.
Gazzaz H, Habchi ME, Feniche ME, Aatik YE, Ouardi AE, Ameur A, et al. Diagnostic and Prognostic Value of miR-93 in Prostate Cancer: A Meta-Analysis and Bioinformatics Analysis. Iran J Public Health. 2023 Oct 29;52(11):2260–71.
Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008 Feb;10(2):202–10.
Majid S, Dar AA, Saini S, Yamamura S, Hirata H, Tanaka Y, et al. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer. 2010 Dec 15;116(24):5637–49.
Hagman Z, Haflidadóttir BS, Ceder JA, Larne O, Bjartell A, Lilja H, et al. miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer. 2013 Apr 30;108(8):1668–76.
Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C, et al. Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene. 2013 Jun 6;32(23):2891–9.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.
Rohatgi A. WebPlotDigitizer User Manual Version 4.6. 2022;
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010 Sep;25(9):603–5.
Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015 Aug 12;4:e05005.
Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 2019 Dec;20(1):18.
Backes C, Kehl T, Stöckel D, Fehlmann T, Schneider L, Meese E, et al. miRPathDB: a new dictionary on microRNAs and target pathways. Nucleic Acids Res. 2017 Jan 4;45(Database issue):D90–6.
Oliveros, J.C. (2007-2015) Venny. An Interactive Tool for Comparing Lists with Venn’s Diagrams. - References - Scientific Research Publishing [Internet]. [cited 2023 Jun 1]. Available from: https://www.scirp.org/(S(lz5mqp453ed%20snp55rrgjct55))/reference/referencespapers.aspx?referenceid=2904043
Thomas PD. The Gene Ontology and the Meaning of Biological Function. Methods Mol Biol Clifton NJ. 2017;1446:15–24.
Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353–61.
Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003 Jan 13;4(1):2.
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia N Y N. 2017 Aug;19(8):649–58.
Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018 Jan 4;46(D1):D956–63.
Rönnau CGH, Fussek S, Smit FP, Aalders TW, van Hooij O, Pinto PMC, et al. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer. World J Urol. 2021 Oct;39(10):3789–97.
Zhang X, Pan Y, Fu H, Zhang J. microRNA-205 and microRNA-338-3p Reduces Cell Apoptosis in Prostate Carcinoma Tissue and LNCaP Prostate Carcinoma Cells by Directly Targeting the B-Cell Lymphoma 2 (Bcl-2) Gene. Med Sci Monit Int Med J Exp Clin Res. 2019 Feb 11;25:1122–32.
Guo X, Han T, Hu P, Guo X, Zhu C, Wang Y, et al. Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention. Int Urol Nephrol. 2018 Dec;50(12):2193–200.
Ghorbanmehr N, Gharbi S, Korsching E, Tavallaei M, Einollahi B, Mowla SJ. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer. The Prostate. 2019 Jan;79(1):88–95.
Li L, Li S. miR-205-5p inhibits cell migration and invasion in prostatic carcinoma by targeting ZEB1. Oncol Lett. 2018 Aug;16(2):1715–21.
Kalogirou C, Spahn M, Krebs M, Joniau S, Lerut E, Burger M, et al. MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. Int J Mol Sci. 2013 Oct 29;14(11):21414–34.
Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al. MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. PloS One. 2013;8(10):e76994.
Wang N, Li Q, Feng NH, Cheng G, Guan ZL, Wang Y, et al. miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. Asian J Androl. 2013 Nov;15(6):735–41.
Tsuchiyama K, Ito H, Taga M, Naganuma S, Oshinoya Y, Nagano K, et al. Expression of MicroRNAs associated with Gleason grading system in prostate cancer: miR‐182‐5p is a useful marker for high grade prostate cancer. The Prostate. 2013 Jun;73(8):827–34.
Gandellini P, Profumo V, Casamichele A, Fenderico N, Borrelli S, Petrovich G, et al. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ. 2012 Nov;19(11):1750–60.
Nordby Y, Richardsen E, Ness N, Donnem T, Patel HRH, Busund LT, et al. High miR-205 expression in normal epithelium is associated with biochemical failure - an argument for epithelial crosstalk in prostate cancer? Sci Rep. 2017 Nov 24;7(1):16308.
Sun Y, Li SH, Cheng JW, Chen G, Huang ZG, Gu YY, et al. Downregulation of miRNA-205 Expression and Biological Mechanism in Prostate Cancer Tumorigenesis and Bone Metastasis. BioMed Res Int. 2020;2020:6037434.
Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers ST, Palisaar RJ, et al. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol. 2013 Jul;43(1):307–14.
Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, Tomm JM, et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene. 2013 Jan 17;32(3):277–85.
Bhatnagar N, Li X, Padi SKR, Zhang Q, Tang M s, Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010 Dec;1(12):e105–e105.
Salem O, Hansen CG. The Hippo Pathway in Prostate Cancer. Cells. 2019 Apr 23;8(4):370.
YAP1 Yes1 associated transcriptional regulator [Homo sapiens (human)] - Gene - NCBI [Internet]. [cited 2023 Jun 7]. Available from: https://www.ncbi.nlm.nih.gov/gene/10413
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008 Apr;28(7):2426–36.
Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010 May;24(9):862–74.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Clinical Science and Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
